Skip to main content
SpringerLink
Log in

Pharmacokinetic Interaction of Tetracycline with Centchroman in Healthy Female Volunteers

  • Original Research Article
  • Published:
Drugs in R & D Aims and scope Submit manuscript

Abstract

Objective: We aimed to investigate the effect of tetracycline coadministration, with and without lactic acid bacillus spores supplementation, on the pharmacokinetics of centchroman, a nonsteroidal oral contraceptive, in healthy female volunteers.

Participants and methods: The study was a single-centre, single-blinded, randomised, parallel treatment study in healthy female subjects of reproductive age randomised to two groups (11 subjects in each group). On day 1, subjects were given either a single oral dose of centchroman 30mg with tetracycline 250mg (group A) or a single dose of centchroman 30mg, tetracycline 250mg and one tablet containing 60 million lactic acid bacillus spores (group B). Tetracycline (250mg three times daily) and lactic acid bacillus spores (one tablet three times daily) were continued for 3 days. Serial blood samples were collected and analysed by high performance liquid chromatography. The pharmacokinetic parameters were compared with the control data reported previously from this laboratory.

Results: Coadministration of tetracycline yielded significantly higher maximum plasma concentrations (Cmax) [35%] and a shorter time to reach Cmax (tmax) values for centchroman (42%) than those obtained in the control group of females (p < 0.05). Inclusion of lactic acid bacillus spores in the regimen resulted in similar effects with increased Cmax (47%) and area under the concentration-time curve from time zero to infinity (34%) of centchroman (p < 0.05) with a significant decrease in tmax. Other parameters such as half-life, apparent clearance, apparent volume of distribution and mean residence time of centchroman were not affected by either of the treatments.

Conclusions: The apparent effects of either of the regimens on centchroman pharmacokinetics seem to be of little clinical relevance in terms of increased rate or extent of availability. It can be concluded that this tetracycline-containing regimen is unlikely to alter the contraceptive efficacy of centchroman in humans.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I

Similar content being viewed by others

Notes

  1. The use of tradenames is for product identification purposes only and does not imply endorsement.

References

  1. Ray S, Grover PK, Anand N. New synthesis of cis- and trans-3-phenyl-4-[4-(β-pyrolidinoethoxy) phenyl]-7-methoxy chromans. Indian J Chem 1971; 9: 727–8

    CAS  Google Scholar 

  2. Singh MM. Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders. Med Res Rev 2001; 21: 302–47

    Article  PubMed  CAS  Google Scholar 

  3. Kamboj VP, Ray S, Dhawan BN. Centchroman. Drugs Today (Barc) 1992; 28: 227–32

    Google Scholar 

  4. Indian Pharmacopoeia. Ormeloxifene hydrochloride. Delhi: Controller of Publications, 1996: 539–40

    Google Scholar 

  5. Misra NC, Nigam PK, Gupta R. Centchroman: a non-steroidal anticancer agent for advanced breast cancer: phase II study. Int J Cancer 1989; 43: 781–3

    Article  PubMed  CAS  Google Scholar 

  6. Labroo VM, Piggott JR, Bain SD. Methods for reducing bone loss using centchroman derivatives. US patent 5464862, 1995

    Google Scholar 

  7. Nityanad S. Centchroman: current status as a contraceptive. Proc X Indian Conf Family Welfare Voluntary Sterilization; JIPMER, Pondicherry, India, 1994: 41–2

    Google Scholar 

  8. Nityanad S, Anand N. Centchroman: a nonsteroidal antifertility agent. FOGSI (Fed Obstet Gynaecol Soc, India) FOCUS 1996, 8–10

    Google Scholar 

  9. Nityanad S, Wati C, Singh L, et al. Clinical evaluation of centchroman: a new oral contraceptive. In: Puri CP, Van Look PFA, editors. Hormone antagonists for fertility control and regulation. India: Indian Society for the Study of Reproduction and Fertility, 1988: 223–30

    Google Scholar 

  10. Lal J, Asthana OP, Nityanand S, et al. Pharmacokinetics of centchroman in healthy female subjects after oral administration. Contraception 1995; 52: 297–300

    Article  PubMed  CAS  Google Scholar 

  11. Paliwal JK, Gupta RC, Grover PK, et al. High performance liquid chromatography determination of centchroman in human serum an application to single-dose pharmacokinetics. Pharm Res 1989; 6: 1048–51

    Article  PubMed  CAS  Google Scholar 

  12. Reynolds JEF, editor. Martindale Extra Pharmacopoeia. London: Royal Pharmaceutical Society, 1996: 285–88

    Google Scholar 

  13. Reynolds JEF, editor. Martindale Extra Pharmacopoeia. London: Royal Pharmaceutical Society, 1996: 1718–19

    Google Scholar 

  14. Murphy A, Zacur HA, Charache P, et al. The effect of tetracycline on oral contraceptives. Am J Obstet Gynecol 1991; 164: 28–33

    PubMed  CAS  Google Scholar 

  15. McLone DG, Billings TE, Hardegree WE, et al. Gonorrhoea in females treated with one oral dose of tetracycline. Br J Vener Dis 1968; 44: 218–9

    PubMed  CAS  Google Scholar 

  16. Stockley IH. Antibiotics and oral contraceptive failure: an update. J Pharmacol 1982; 6: 525–8

    Google Scholar 

  17. Back DJ, Grimmer SFM, Orme ML’E, et al. Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics. Br J Clin Pharmacol 1988; 25: 527–32

    Article  PubMed  CAS  Google Scholar 

  18. Weisberg E. Interactions between oral contraceptives and antifungals/antibacterials: is contraceptive failure the result? Clin Pharmacokinet 1999; 36: 309–13

    Article  PubMed  CAS  Google Scholar 

  19. Ghosh R, Kamboj VP, Singh MM. Interaction with anti-implantation and estrogen antagonistic activities of dl-ormeloxifene, a selective estrogen receptor modulator, by tetracycline in female Sprague-Dawley rats. Contraception 2001; 64: 261–9

    Article  PubMed  CAS  Google Scholar 

  20. Khurana M, Lal J, Singh MM, et al. Evaluation of interaction potential of certain concurrently administered drugs with pharmacological and pharmacokinetic profile of centchroman in rats. Contraception 2002; 66: 47–56

    Article  PubMed  CAS  Google Scholar 

  21. Weaver K, Glasier A. Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill. Contraception 1999; 59: 71–8

    Article  PubMed  CAS  Google Scholar 

  22. Davies DM. Textbook of adverse drug reactions. USA: Oxford University Press, 1986: 233–49

    Google Scholar 

  23. Lal J, Paliwal JK, Grover PK, et al. Simultaneous liquid chromatography determination of centchroman and its 7-demethylated metabolite in serum and milk. J Chromatogr B 1994; 658: 193–7

    Article  CAS  Google Scholar 

  24. Batt RM, Rutgers HC, Sancak AA. Enteric bacteria: friend or foe? J Small Anim Pract 1996; 37: 261–7

    Article  PubMed  CAS  Google Scholar 

  25. Simon GL, Gorbach SL. The human intestinal microflora. Dig Dis Sci 1986; 31: 147S–62S

    Article  PubMed  CAS  Google Scholar 

  26. Obach RS, Baxter JT, Listen TE, et al. Prediction of human pharmacokinetic parameters from pre-clinical and in vitro metabolism data. J Pharmacol Exp Ther 1997; 283: 46–8

    PubMed  CAS  Google Scholar 

  27. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093–5

    Article  PubMed  CAS  Google Scholar 

  28. Lal J, Nityanand S, Asthana OP, et al. Comparative biavailability of two commercial centchroman tablets in healthy female subjects. Indian J Pharmacol 1996; 28: 32–4

    CAS  Google Scholar 

Download references

Acknowledgements

The authors thank Dr C.M. Gupta, director of this institute, for providing the facilities for conducting this study. The financial assistance by the Council of Scientific and Industrial Research, India (Emeritus Scientist project #21(410)/97/EMR-II) for VPK and MK is gratefully acknowledged. The authors have no conflicts of interest directly relevant to the content of this study.’

Author information

Authors and Affiliations

  1. Pharmacokinetics and Metabolism Division, Central Drug Research Institute, Post Box 173, Lucknow, 226001, India

    Manoj Khurana, Jawahar Lal &  Ram C. Gupta

  2. Endocrinology Division, Central Drug Research Institute, Lucknow, India

    Ved P. Kamboj

  3. Clinical and Experimental Medicine Division, Central Drug Research Institute, Lucknow, India

    Swaran Nityanand

Authors
  1. Manoj Khurana
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jawahar Lal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ved P. Kamboj
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Swaran Nityanand
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ram C. Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ram C. Gupta.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Khurana, M., Lal, J., Kamboj, V.P. et al. Pharmacokinetic Interaction of Tetracycline with Centchroman in Healthy Female Volunteers. Drugs R&D 4, 293–299 (2003). https://doi.org/10.2165/00126839-200304050-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200304050-00003

Keywords

Search

Navigation